Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXELIXIS, INC.EXEL · Entity 3386 | Director | May 27, 2026 | May 29, 2026 |
| Liquidia CorpLQDA · Entity 1860 | Director · 10% owner | June 16, 2026 | June 18, 2026 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | 10% owner | June 29, 2023 | July 03, 2023 |
| Verrica Pharmaceuticals Inc.VRCA · Entity 6823 | See Remarks | December 26, 2025 | December 30, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXELIXIS, INC.
Report date May 27, 2026 · Filed May 29, 2026
Jointly reported with Caligan Partners LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.03 · Expires 2033-05-26 | Direct | 19,133 |
Reported balance
After 2026-05-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 19,133 · Balance 19,133 F1: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date. F2: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date.
F2: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts.
Liquidia Corp
Report date June 16, 2026 · Filed June 18, 2026
Jointly reported with Caligan Partners LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per share ("Common Stock")SEC Table I · non-derivative | Direct | 5,882 |
Reported balance
After 2026-06-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 5,882 · Balance 5,882 F1: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis. F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. F3: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 8,157,347 |
Reported balance
Holding disclosure · report date 2026-06-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 8,157,347 F4: Securities held by the Caligan Funds and Accounts to which Caligan serves as investment manager and related entities. Mr. Johnson (together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis.
F2: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant.
F3: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts.
F4: Securities held by the Caligan Funds and Accounts to which Caligan serves as investment manager and related entities. Mr. Johnson (together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
STANDARD BIOTOOLS INC.
Report date June 29, 2023 · Filed July 03, 2023
Jointly reported with Caligan Partners LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnote | 8,467,920 |
Reported balance
After 2023-06-29 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-29 · Other · Disposed 108,879 · Balance 8,467,920 F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan. F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 7,797,454 |
Reported balance
After 2023-07-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-07-03 · Other · Disposed 670,466 · Balance 7,797,454 F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan. F3: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager. F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan.
F2: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F3: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager.
Verrica Pharmaceuticals Inc.
Report date December 26, 2025 · Filed December 30, 2025
Jointly reported with Caligan Partners LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001 per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnote | 923,910 |
Reported balance
Holding disclosure · report date 2025-12-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 923,910 F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Pre-Funded Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-26 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: The Pre-Funded Warrants will not expire until exercised in full. F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker. F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Series C Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.32 · Expires 2030-11-25 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-26 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker. F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Series B Warrants (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.35 · Expires 2029-11-22 | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2025-12-26 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker. F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 3 is filed by Caligan Partners LP ("Caligan") and David Johnson with respect to the securities held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and managed accounts to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F2: The Pre-Funded Warrants will not expire until exercised in full.
F3: Pursuant to the terms of the Pre-Funded Warrants, the Series C Warrants and the Series B Warrants (collectively, the "Warrants"), the Reporting Persons cannot exercise any of the Warrants to the extent the Reporting Persons would beneficially own, after any such exercise, more than 9.99% of the outstanding Common Stock (the "9.99% Blocker"). Consequently, at this time, the Reporting Persons are not able to exercise all of the Warrants reported herein due to the 9.99% Blocker.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALIMERA SCIENCES INC
Report date September 16, 2024 · Filed September 18, 2024
Jointly reported with Caligan Partners LP
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.01 per share ("Common Stock")SEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-09-16 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-09-16 · Other · Disposed 16,835,154 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2030-03-24 | IndirectSee footnote | 0 |
Reported balance
After 2024-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-16 · Other · Disposed 800,000 · Balance 0 F3: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Notional Derivative Agreements (obligation to buy)SEC Table II · derivative / convertible security · Expires 2025-09-26 | IndirectSee footnote | 0 |
Reported balance
After 2024-09-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-09-16 · Other · Disposed 1 · Balance 0 F4: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").
F2: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F3: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement.
F4: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 14,676 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 3,499,428 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F3: Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 9,452 · Balance 0 F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a.r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Such securities are held by an affiliated fund and managed account to which Caligan Partners LP ("Caligan") serves as investment manager. David Johnson is the Partner of Caligan and Managing Member of Caligan Partners GP LLC, the general partner of Caligan.
F4: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 16, 2026 Filed Jun 18, 2026 21:30 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock, $0.001 par value per share ("Common Stock") | 5,882 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-26-002852 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,882 F1 · kind: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. F3 · ownership.direct: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts. Read SEC document |
| May 27, 2026 Filed May 29, 2026 20:30 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 19,133 | $0.00 Strike: $50.03 | $0.00 |
DisclosureSEC source: 0000902664-26-002641 · ownership.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,133 Underlying: Common Stock · 19,133 shares Expires 2033-05-26 F1 · derivative.exercise_date: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date. F2 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts. Read SEC document |
| May 19, 2026 Filed May 21, 2026 00:51 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock | 5,300 | $59.98 | $317,894.00 |
DisclosureSEC source: 0000902664-26-002578 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,138,951 F2 · kind: Represents a transaction between the Caligan Funds. F1 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 19, 2026 Filed May 21, 2026 00:51 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock, $0.001 par value per share ("Common Stock") | 5,300 | $59.98 | $317,894.00 |
DisclosureSEC source: 0000902664-26-002578 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,133,651 F2 · kind: Represents a transaction between the Caligan Funds. F1 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| November 25, 2025 Filed Nov 26, 2025 21:05 UTC | EXELIXIS, INC. EXEL · Entity 3386 | PurchaseCommon Stock | 27,532 | $43.12 | $1,187,234.90 |
DisclosureSEC source: 0000902664-25-005164 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,553,262 F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 17, 2025 Filed Jun 20, 2025 20:10 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock, $0.001 par value per share ("Common Stock") | 18,396 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-25-002766 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,755 F1 · kind: Restricted stock units ("RSUs") convert into Common Stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. F3 · ownership.direct: David Johnson ("Mr. Johnson") is deemed to hold the securities reported herein for the benefit of certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds and Accounts. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 21:22 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 21,464 | $0.00 Strike: $42.60 | $0.00 |
DisclosureSEC source: 0000902664-25-002613 · ownership.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,464 Underlying: Common Stock · 21,464 shares Expires 2032-05-28 F1 · derivative.exercise_date: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date. F2 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Fund and Accounts. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 16:30 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | OtherNotional Derivative Agreements (obligation to buy) · Derivative | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-005552 · ownership.xml · derivative · entry 3 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 490,000 shares Expires 2025-09-26 F4 · security: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F4 · derivative.exercise_price: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F4 · kind: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F4 · price: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F4 · derivative.exercise_date: As a result of the closing of the merger, the derivative agreements held by the Caligan Funds and Accounts settled in accordance with their terms based on the Merger Consideration. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 16:30 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | OtherWarrants · Derivative | 800,000 | Not disclosed Strike: $2.10 | Not disclosed |
DisclosureSEC source: 0000902664-24-005552 · ownership.xml · derivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 800,000 shares Expires 2030-03-24 F3 · kind: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. F3 · price: Immediately prior to the Effective Time, the warrants to purchase shares of Common Stock were net exercised and the resulting shares of Common Stock were converted into the right to receive the Merger Consideration pursuant to the terms of the Merger Agreement. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 16:30 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | OtherCommon Stock, par value $0.01 per share ("Common Stock") | 16,835,154 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-005552 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of June 21, 2024, by and among ANI Pharmaceuticals, Inc., a Delaware corporation ("ANI") and Alimera Sciences, Inc., a Delaware corporation (the "Issuer") and the other parties thereto (the "Merger Agreement") as of the effective time of the merger (the "Effective Time"), each outstanding share of Common Stock was cancelled and ceased to exist and converted into the right to receive (i) $5.50 in cash, without interest and (ii) one contingent value right representing the right to receive contingent cash payments subject to the achievement of certain milestones and the terms and conditions set forth in a contingent value rights agreement entered into between ANI and a rights agent (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities previously held by Caligan Partners Master Fund LP, a Cayman Islands limited partnership, and certain funds and managed accounts to which Caligan serves as investment manager (the "Caligan Funds and Accounts"). Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 12, 2024 Filed Sep 12, 2024 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock, $0.001 par value per share ("Common Stock") | 1,123,595 | $8.90 | $9,999,995.50 |
DisclosureSEC source: 0000902664-24-005485 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,118,592 F1 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan Partners LP ("Caligan") serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:51 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock | 150,000 | $9.51 | $1,426,500.00 |
DisclosureSEC source: 0000902664-24-005425 · ownership.xml · nonDerivative · entry 3 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,994,997 F4 · kind: Represents a transaction between the Caligan Funds. F3 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:51 UTC | Liquidia Corp LQDA · Entity 1860 | SaleCommon Stock | 150,000 | $9.51 | $1,426,500.00 |
DisclosureSEC source: 0000902664-24-005425 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,844,997 F4 · kind: Represents a transaction between the Caligan Funds. F3 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 30, 2024 Filed Sep 4, 2024 21:51 UTC | Liquidia Corp LQDA · Entity 1860 | OtherCommon Stock, $0.001 par value per share ("Common Stock") | 3,440,948 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-24-005425 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 6,994,997 F1 · kind: This transaction represents a pro-rata in-kind distribution by a Caligan Fund (as defined below) to limited partners for no consideration effected as of the close of trading on August 30, 2024. The shares of Common Stock were not disposed of in a sale transaction. F1 · price: This transaction represents a pro-rata in-kind distribution by a Caligan Fund (as defined below) to limited partners for no consideration effected as of the close of trading on August 30, 2024. The shares of Common Stock were not disposed of in a sale transaction. F2 · balance_after: Effective as of the close of trading on August 30, 2024, a consulting arrangement with a managed account to which Caligan (as defined below) served as a consultant (the "Consulting Arrangement") was terminated pursuant to its terms, and accordingly, 845,000 shares of Common Stock which were previously reported by the Reporting Persons (as defined below) that were subject to the Consulting Arrangement are no longer reported herein. The ommon Stock were not disposed of in a sale transaction. 75,000 shares of Common Stock that were previously subject to the Consulting Arrangement were received by Caligan pursuant to amounts due under the terms of the Consulting Arrangement and continue to be reported herein. F3 · ownership.nature: Securities held by certain funds (the "Caligan Funds") and managed accounts (the "Caligan Accounts", and together with the Caligan Funds, the "Caligan Funds and Accounts") to which Caligan serves as investment manager and related entities. David Johnson ("Mr. Johnson", and together with Caligan, the "Reporting Persons") is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 20, 2024 Filed Jun 25, 2024 01:37 UTC | Liquidia Corp LQDA · Entity 1860 | GrantCommon Stock, $0.001 par value per share ("Common Stock") | 20,359 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-074471 · tm2418154-4_4seq1.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,359 F1 · kind: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. F2 · shares: The RSUs shall vest upon the earlier of (i) the one-year anniversary of the date of grant or (ii) the day prior to the Issuer's next annual shareholder meeting following the date of grant. F3 · balance_after: Mr. Johnson is deemed to hold the securities reported herein for the benefit of certain affiliated funds (the "Caligan Funds") to which Caligan Partners LP ("Caligan") serves as investment manager and a managed account to which Caligan serves as a consultant, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds or managed account. F3 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of certain affiliated funds (the "Caligan Funds") to which Caligan Partners LP ("Caligan") serves as investment manager and a managed account to which Caligan serves as a consultant, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds or managed account. Read SEC document |
| May 31, 2024 Filed Jun 4, 2024 21:10 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 42,767 | $0.00 Strike: $21.69 | $0.00 |
DisclosureSEC source: 0000902664-24-004028 · ownership.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks. Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,767 Underlying: Common Stock · 42,767 shares Expires 2031-05-30 F1 · derivative.exercise_date: Option granted to David Johnson ("Mr. Johnson") pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 100% of the shares subject to the option on the first anniversary of the date of grant, subject to Mr. Johnson's continuous service through such date. F2 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Master Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts", together with the Caligan Master Fund, the "Caligan Master Fund and Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Master Fund and Accounts. Read SEC document |
| May 30, 2024 Filed May 30, 2024 23:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | PurchaseCommon Stock | 225,000 | $20.76 | $4,670,055.00 |
DisclosureSEC source: 0000902664-24-003949 · ownership.xml · nonDerivative · entry 2 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,525,730 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased by Caligan Master Fund (as defined below) in multiple transactions at prices ranging from $20.40 to $20.885, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 28, 2024 Filed May 30, 2024 23:50 UTC | EXELIXIS, INC. EXEL · Entity 3386 | PurchaseCommon Stock | 200,000 | $20.32 | $4,063,900.00 |
DisclosureSEC source: 0000902664-24-003949 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,300,730 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased by Caligan Master Fund (as defined below) in multiple transactions at prices ranging from $20.22 to $20.375, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| February 21, 2024 Filed Feb 22, 2024 22:08 UTC | EXELIXIS, INC. EXEL · Entity 3386 | PurchaseCommon Stock | 190,000 | $20.70 | $3,932,734.00 |
DisclosureSEC source: 0000902664-24-001966 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 1,100,730 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased by Caligan Master Fund (as defined below) in multiple transactions at prices ranging from $20.57 to $20.78, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| December 14, 2023 Filed Dec 14, 2023 21:42 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 1,117,318 | $7.16 | $7,999,996.88 |
DisclosureSEC source: 0000902664-23-005873 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 11,280,945 F1 · balance_after: Since the filing of the Form 4 filed by the Reporting Persons on September 7, 2022, and more than 6 months ago, the managed account to which Caligan (as defined below) serves as a consultant has reduced its holding by 480,000 shares of Common Stock, and accordingly, such shares of Common Stock are no longer included in the total amount of securities beneficially owned that are reported in Column 5. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan" and together with Mr. Johnson, the "Reporting Persons") with respect to the securities held by (i) Caligan Partners Master Fund LP, a Cayman Islands limited partnership, (ii) an affiliated fund to which Caligan serves as investment manager, (iii) managed accounts to which Caligan serves as investment manager, and (iv) a managed account to which Caligan serves as a consultant. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:30 UTC | EXELIXIS, INC. EXEL · Entity 3386 | PurchaseCommon Stock | 120,409 | $21.61 | $2,602,038.49 |
DisclosureSEC source: 0000902664-23-005732 · ownership.xml · nonDerivative · entry 2 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 910,730 F2 · shares: Represents a rebalancing transaction between the Caligan Fund and Accounts. F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 21:30 UTC | EXELIXIS, INC. EXEL · Entity 3386 | SaleCommon Stock | 120,409 | $21.61 | $2,602,038.49 |
DisclosureSEC source: 0000902664-23-005732 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 790,321 F2 · shares: Represents a rebalancing transaction between the Caligan Fund and Accounts. F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 16:05 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | OtherNotional Derivative Agreements (obligation to buy) · Derivative | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-23-004790 · ownership.xml · derivative · entry 3 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 490,000 Underlying: Common Stock · 490,000 shares Expires not disclosed F2 · security: Represents rebalancing transaction between the Caligan Fund and Accounts. F3 · derivative.exercise_price: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F3 · kind: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F3 · shares: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F3 · price: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F3 · derivative.exercise_date: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F3 · derivative.expiration_date: At the market close on September 14, 2023, the expiration date of the notional principal amount derivative agreements in the form of cash settled swaps previously reported on the Form 3 filed by the Reporting Persons on August 11, 2023, was extended from February 2, 2024 to September 26, 2025. F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 16:05 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | PurchaseCommon Stock | 579,000 | $3.39 | $1,962,810.00 |
DisclosureSEC source: 0000902664-23-004790 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,835,154 F2 · shares: Represents rebalancing transaction between the Caligan Fund and Accounts. F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| September 14, 2023 Filed Sep 15, 2023 16:05 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | SaleCommon Stock, par value 0.01 per share (Common Stock) | 579,000 | $3.39 | $1,962,810.00 |
DisclosureSEC source: 0000902664-23-004790 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,256,154 F2 · shares: Represents rebalancing transaction between the Caligan Fund and Accounts. F1 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Fund and Accounts") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 19:01 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | ConversionSeries B Preferred · Derivative | 13,431,616 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000902664-23-004504 · ownership.xml · derivative · entry 4 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,431,616 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F1 · derivative.exercise_date: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F1 · derivative.expiration_date: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Purchasers") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 19:01 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | ConversionSeries B Preferred · Derivative | 2,924,761 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0000902664-23-004504 · ownership.xml · derivative · entry 3 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 2,924,761 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F1 · derivative.exercise_date: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F1 · derivative.expiration_date: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Purchasers") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 19:01 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | ConversionCommon Stock | 13,431,616 | $1.70 | $22,833,747.20 |
DisclosureSEC source: 0000902664-23-004504 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 16,835,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Purchasers") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 19:01 UTC | ALIMERA SCIENCES INC ALIM · Entity 11664 | ConversionCommon Stock, par value $0.01 per share ("Common Stock") | 2,924,761 | $2.10 | $6,141,998.10 |
DisclosureSEC source: 0000902664-23-004504 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 3,403,538 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On August 15, 2023, the Series B Preferred held by the Caligan Purchasers (as defined below) automatically converted to shares of Common Stock pursuant to their terms. The Series B Preferred had no stated maturity. F2 · ownership.nature: This Form 4 is filed by David Johnson ("Mr. Johnson") and Caligan Partners LP ("Caligan") with respect to the securities held by Caligan Partners Master Fund LP ("Caligan Master Fund"), a Cayman Islands limited partnership, and managed accounts ("Caligan Accounts", together with the Caligan Master Fund, the "Caligan Purchasers") to which Caligan serves as investment manager. Mr. Johnson is the Managing Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| July 03, 2023 Filed Jul 3, 2023 21:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock | 670,466 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-23-003816 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 7,797,454 F1 · kind: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan. F3 · price: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager. F3 · balance_after: This transaction represents an in-kind distribution by certain funds and accounts to which Caligan serves as the investment manager. F2 · ownership.nature: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 29, 2023 Filed Jul 3, 2023 21:18 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | OtherCommon Stock, $0.001 par value per share ("Common Stock") | 108,879 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000902664-23-003816 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 8,467,920 F1 · price: Represents the total number of shares of Common Stock beneficially owned by Caligan Partners LP ("Caligan") following the termination of an investment management agreement with respect to an account previously managed by Caligan. F2 · ownership.nature: The securities reported herein are held by an affiliated fund of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 19, 2023 Filed Jun 21, 2023 21:22 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0000902664-23-003669 · ownership.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-06-19 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 19, 2026. F2 · balance_after: Mr. Johnson is deemed to hold the securities reported herein for the benefit of certain affiliated funds (the "Caligan Funds") to which Caligan Partners LP ("Caligan") serves as investment manager and a managed account to which Caligan serves as a consultant, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds or managed account. F2 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of certain affiliated funds (the "Caligan Funds") to which Caligan Partners LP ("Caligan") serves as investment manager and a managed account to which Caligan serves as a consultant, and may, after vesting, if applicable, transfer the securities directly to such Caligan Funds or managed account. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantOption (right to buy) · Derivative | 36,353 | $0.00 Strike: $19.28 | $0.00 |
DisclosureSEC source: 0000902664-23-003404 · ownership.xml · derivative · entry 3 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,353 Underlying: Common Stock · 36,353 shares Expires 2030-05-30 F5 · derivative.exercise_date: Option granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The option is exercisable immediately, subject to repurchase provisions, and will vest as to 1/4th of the original number of shares subject to the option on the one-year anniversary of the Transaction Date, and thereafter as to 1/48th of the original number of shares subject to the option on each monthly anniversary of the Transaction Date, subject to Mr. Johnson's continuous service through such dates. F3 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Fund and the Caligan Accounts. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 21:06 UTC | EXELIXIS, INC. EXEL · Entity 3386 | GrantCommon Stock | 18,176 | $0.00 | $0.00 |
DisclosureSEC source: 0000902664-23-003404 · ownership.xml · nonDerivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director Caligan Partners LP · CIK 0001727492 · Director · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,176 F1 · security: Represents shares of Exelixis, Inc. (the "Issuer") common stock ("Common Stock") issued to David Johnson ("Mr. Johnson") upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Common Stock. F2 · date: The restricted stock units were granted to Mr. Johnson on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the original number of shares subject to the restricted stock unit award on each of the first four anniversaries of the Transaction Date, subject to the Mr. Johnson's continuous service through such dates. F3 · ownership.direct: Mr. Johnson is deemed to hold the securities reported herein for the benefit of Caligan Partners Master Fund LP (the "Caligan Fund") and managed accounts to which Caligan Partners LP ("Caligan") serves as investment manager (the "Caligan Accounts"), and may, after vesting, if applicable, transfer the securities directly to the Caligan Fund and the Caligan Accounts. Read SEC document |
| September 06, 2022 Filed Sep 7, 2022 13:15 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 250,000 | $5.62 | $1,405,000.00 |
DisclosureSEC source: 0000902664-22-004182 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,643,627 F1 · price: Price is the volume weighted average purchase price of all purchases by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $5.47 to $5.77. F2 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 04, 2022 Filed Aug 5, 2022 15:10 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 255,173 | $1.75 | $446,552.75 |
DisclosureSEC source: 0000902664-22-003823 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,444,836 F2 · price: Price is the volume weighted average price of all trades by the Reporting Persons on the transaction date for prices ranging from $1.71 to $1.77. F4 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F3 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 03, 2022 Filed Aug 5, 2022 15:10 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 46,009 | $1.74 | $80,055.66 |
DisclosureSEC source: 0000902664-22-003823 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,189,663 F1 · price: Price is the volume weighted average price of all trades by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $1.70 to $1.75. F4 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F3 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 02, 2022 Filed Aug 2, 2022 21:27 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 272,618 | $1.64 | $447,093.52 |
DisclosureSEC source: 0000902664-22-003778 · ownership.xml · nonDerivative · entry 3 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 11,143,654 F3 · price: Price is the volume weighted average price of all trades by the Reporting Persons on the transaction date for prices ranging from $1.49 to $1.70. F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F4 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| August 01, 2022 Filed Aug 2, 2022 21:27 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 210,200 | $1.48 | $311,096.00 |
DisclosureSEC source: 0000902664-22-003778 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,871,036 F2 · price: Price is the volume weighted average price of all trades by the Reporting Persons on the transaction date for prices ranging from $1.40 to $1.52. F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F4 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 21:27 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share (Common Stock) | 137,648 | $1.42 | $195,460.16 |
DisclosureSEC source: 0000902664-22-003778 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,660,836 F1 · price: Price is the volume weighted average price of all trades by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $1.37 to $1.45. F5 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F4 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 17, 2022 Filed Jun 22, 2022 20:31 UTC | Liquidia Corp LQDA · Entity 1860 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.86 | $0.00 |
DisclosureSEC source: 0001104659-22-073526 · tm2219055-2_4seq1.xml · derivative · entry 1 JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-17 F1 · derivative.exercise_date: The option vests in 36 equal monthly installments and will become fully vested on June 17, 2025. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 13:06 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 100,000 | $1.70 | $170,000.00 |
DisclosureSEC source: 0000902664-22-003296 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,523,188 F1 · price: Price is the volume weighted average price of all trades by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $1.64 to $1.75. F3 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares traded at each separate price. F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 18:01 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $1.98 | $495,000.00 |
DisclosureSEC source: 0000902664-22-003177 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,423,188 F3 · price: Price is the volume weighted average selling price of all sales by the Reporting Persons on the transaction date for prices ranging from $1.92 to $2.02. F4 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| June 02, 2022 Filed Jun 6, 2022 18:01 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 200,000 | $1.92 | $384,000.00 |
DisclosureSEC source: 0000902664-22-003177 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,173,188 F1 · price: Price is the volume weighted average selling price of all sales by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $1.83 to $2.00. F4 · price: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price. F2 · ownership.nature: The securities reported herein are held by an affiliated fund and managed account of Caligan. David Johnson is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 25, 2022 Filed May 26, 2022 12:47 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 79,400 | $3.40 | $269,960.00 |
DisclosureSEC source: 0000902664-22-003105 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,393,627 F1 · price: Price is the volume weighted average purchase price of all purchases by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $3.32 to $3.48. F2 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 19, 2022 Filed May 19, 2022 22:16 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock | 85,000 | $5.81 | $493,850.00 |
DisclosureSEC source: 0000902664-22-003037 · ownership.xml · nonDerivative · entry 3 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,314,227 F3 · price: Price is the volume weighted average purchase price of all purchases by the Reporting Persons on the transaction date for prices ranging from $5.53 to $5.92. F4 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 18, 2022 Filed May 19, 2022 22:16 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock | 76,404 | $5.89 | $450,019.56 |
DisclosureSEC source: 0000902664-22-003037 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,229,227 F2 · price: Price is the volume weighted average purchase price of all purchases by the Reporting Persons on the transaction date for prices ranging from $5.56 to $6.07. F4 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 17, 2022 Filed May 19, 2022 22:16 UTC | Liquidia Corp LQDA · Entity 1860 | PurchaseCommon Stock, $0.001 par value per share ("Common Stock") | 59,700 | $5.99 | $357,603.00 |
DisclosureSEC source: 0000902664-22-003037 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · Director · 10% owner · See Remarks JOHNSON DAVID EDWARD · CIK 0001785557 · Director · 10% owner · See Remarks Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 10,152,823 F1 · price: Price is the volume weighted average purchase price of all purchases by Caligan Partners LP ("Caligan") and David Johnson (together with Caligan, the "Reporting Persons") on the transaction date for prices ranging from $5.75 to $6.08. F4 · ownership.nature: The securities reported herein are held by an affiliated fund to which Caligan serves as investment manager and a managed account to which Caligan serves as a consultant. David Johnson is the Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. Read SEC document |
| May 10, 2022 Filed May 11, 2022 01:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 25,000 | $2.52 | $63,000.00 |
DisclosureSEC source: 0000902664-22-002849 · ownership.xml · nonDerivative · entry 2 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,973,188 F1 · price: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson (together with Caligan, the "Reporting Persons") is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. F2 · ownership.nature: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price. Read SEC document |
| May 06, 2022 Filed May 11, 2022 01:03 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock, $0.001 par value per share (Common Stock) | 463,350 | $2.90 | $1,343,715.00 |
DisclosureSEC source: 0000902664-22-002849 · ownership.xml · nonDerivative · entry 1 Caligan Partners LP · CIK 0001727492 · 10% owner JOHNSON DAVID EDWARD · CIK 0001785557 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 9,948,188 F1 · price: The securities reported herein are held by an affiliated fund and managed account of Caligan Partners LP ("Caligan"). David Johnson (together with Caligan, the "Reporting Persons") is a Partner of Caligan and a Managing Member of Caligan Partners GP LLC, the general partner of Caligan. F2 · ownership.nature: The Reporting Persons hereby undertake to provide upon request of the staff of the Securities and Exchange Commission full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.